摘要
针对高恶性骨肉瘤,临床传统上可实现的化疗法被内在的因素或获得性药物耐药性严重地限制,以往的研究已强调了主要因素是ABCB1(MDR1/P-糖蛋白类)的过度表达。本文主要目的是估测一组ATP结合盒转运体的骨肉瘤药物耐药性的影响,在其他人的肿瘤中表现出的对药物无反应性已成为骨肉瘤(阿霉素、甲氨蝶呤、顺铂)多药物治疗方案的基础。通过对人类骨肉瘤细胞系进行了一组包括6个药敏实验和20个耐药实验,除了ABCB1,被证明与骨肉瘤细胞中药物耐药性的程度相关性最高的转运体是ABCC1。因此,我们评估了口服式可管理的ABCB1/ABCC1抑制因子CBT-1® (粉防乙碱,NSC-77037)。我们发现在我们研究的骨肉瘤细胞系中,该剂型作为这些转运体的基体(泰索帝、依托泊苷、长春瑞滨)可恢复由ABCB1/ABCC1介导的抵抗阿霉素耐药性,同时能够抵抗被用于骨肉瘤二线治疗的药物。我们的发现表明阻止传统化疗药物作用中具有CBT-1的ABCB1和ABCC1的活性,对反应迟钝型或恶性骨肉瘤病人来说可能会是成为一种能引起关注的新型治疗方案。
关键词: ABC转运体,化疗增敏、化学疗法、药物耐药性、骨肉瘤、特定治疗方案。
图形摘要
Current Cancer Drug Targets
Title:Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma
Volume: 16 Issue: 3
Author(s): Marilu Fanelli, Claudia Maria Hattinger, Serena Vella, Elisa Tavanti, Francesca Michelacci, and Beth Gudeman, Daryl Barnett, Piero Picci and Massimo Serra
Affiliation:
关键词: ABC转运体,化疗增敏、化学疗法、药物耐药性、骨肉瘤、特定治疗方案。
摘要: Clinical treatment response achievable with conventional chemotherapy in high-grade osteosarcoma (OS) is severely limited by the presence of intrinsic or acquired drug resistance, which in previous studies has been mainly addressed for overexpression of ABCB1 (MDR1/P-glycoprotein). This study was aimed to estimate the impact on OS drug resistance of a group of ATP binding cassette (ABC) transporters, which in other human tumors have been associated with unresponsiveness to the drugs that represent the backbone of multidrug treatment regimens for OS (doxorubicin, methotrexate, cisplatin).
By using a group of 6 drug-sensitive and 20 drug-resistant human OS cell lines, the most relevant transporter which proved to be associated with the degree of drug resistance in OS cells, in addition to ABCB1, was ABCC1. We therefore evaluated the in vitro activity of the orally administrable ABCB1/ABCC1 inhibitor CBT-1® (Tetrandrine, NSC-77037). We found that in our OS cell lines this agent was able to revert the ABCB1/ABCC1-mediated resistance against doxorubicin, as well as against the drugs used in second-line OS treatments that are substrates of these transporters (taxotere, etoposide, vinorelbine). Our findings indicated that inhibiting ABCB1 and ABCC1 with CBT-1®, used in association with conventional chemotherapeutic drugs, may become an interesting new therapeutic option for unresponsive or relapsed OS patients.
Export Options
About this article
Cite this article as:
Marilu Fanelli, Claudia Maria Hattinger, Serena Vella, Elisa Tavanti, Francesca Michelacci, and Beth Gudeman, Daryl Barnett, Piero Picci and Massimo Serra , Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/1568009616666151106120434
DOI https://dx.doi.org/10.2174/1568009616666151106120434 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Structure and Function of the Epstein-Barr Virus Transcription Factor, EBNA 3C
Current Protein & Peptide Science Tumor Targeting with RGD Peptide Ligands-Design of New Molecular Conjugates for Imaging and Therapy of Cancers
Anti-Cancer Agents in Medicinal Chemistry Bone Modulating Bioactive Natural Compounds: Review
Current Bioactive Compounds Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Augmenting T Helper Cell Immunity in Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders In <i>Vitro</i> Cytotoxicity Evaluation of Oxytetracycline Loaded Cockle Shell Derived Calcium Carbonate Aragonite Nanoparticles
Nanoscience & Nanotechnology-Asia Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Non-coding RNAs as Novel Biomarkers in Cancer Drug Resistance
Current Medicinal Chemistry Mechanisms Controlling Sensitivity to Platinum Complexes: Role of p53 and DNA Mismatch Repair
Current Cancer Drug Targets Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds